|Traded as||NYSE: PFE (component of Dow 30 and S&P 500)|
|Headquarters||New York City, U.S.|
|Revenue||US$51.584 billion (2013)|
|Operating income||US$15.716 billion (2013)|
|Net income||US$22.003 billion (2013)|
|Total assets||US$172.101 billion (2013) |
|Total equity||US$76.620 billion (2013)|
|Subsidiaries||Agouron Pharmaceuticals, G. D. Searle & Company, Innopharma, Greenstone, Parke-Davis, Pfizer UK, Warner Lambert, Wyeth, Zoetis|
|Footnotes / references
Pfizer, Inc. // is an American multinational pharmaceutical corporation headquartered in New York City, and with its research headquarters in Groton, Connecticut, United States. It is one of the world's largest pharmaceutical companies by revenues.
Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer's products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin for neuropathic pain/fibromyalgia); Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil, for erectile dysfunction); and Celebrex/Celebra (celecoxib), an anti-inflammatory drug.
Pfizer was founded by cousins Charles Pfizer and Charles F. Erhart in New York City in 1849 as a manufacturer of fine chemicals. Pfizer's discovery of Terramycin (oxytetracycline) in 1950 put it on a path towards becoming a research-based pharmaceutical company. Pfizer has made numerous acquisitions, including Warner–Lambert in 2000, Pharmacia in 2003 and Wyeth in 2009. The Wyeth acquisition was the largest of the three at US$68 billion. Pfizer is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since April 2004.
In September 2009, Pfizer pleaded guilty to the illegal marketing of the arthritis drug Bextra for uses unapproved by the U.S. Food and Drug Administration (FDA), and agreed to a $2.3 billion settlement, the largest health care fraud settlement at that time. Pfizer also paid the U.S. government $1.3 billion in criminal fines related to the "off-label" marketing of Bextra, the largest monetary penalty ever rendered for any crime. Called a repeat offender by prosecutors, this was Pfizer's fourth such settlement with the U.S. Department of Justice in the previous ten years.
- 1 History
- 2 Operations
- 3 Products
- 4 Promotional practices
- 5 Litigation
- 6 Environmental record
- 7 Political lobbying
- 8 Employment and diversity
- 9 Involvement in Developing World Health Issues
- 10 See also
- 11 References
Pfizer is named after German-American cousins Charles Pfizer and Charles F. Erhart (originally from Ludwigsburg, Germany) who launched a chemicals business, Charles Pfizer and Company, from a building at the intersection of Harrison Avenue and Bartlett Street in Williamsburg, Brooklyn, in 1849. There, they produced an antiparasitic called santonin. This was an immediate success, although it was the production of citric acid that really kick-started Pfizer's growth in the 1880s. Pfizer continued to buy property to expand its lab and factory on the block bounded by Bartlett Street; Harrison Avenue; Gerry Street; and Flushing Avenue. Pfizer's original administrative headquarters was at 81 Maiden Lane in Manhattan.
By 1906, sales totaled $3.4 million.
World War I caused a shortage of calcium citrate that Pfizer imported from Italy for the manufacture of citric acid, and the company began a search for an alternative supply. Pfizer chemists learned of a fungus that ferments sugar to citric acid and were able to commercialize production of citric acid from this source in 1919. As a result Pfizer developed expertise in fermentation technology. These skills were applied to the mass production of the antibiotic penicillin during World War II in response to the need of the U.S. government to treat injured Allied soldiers; most of the penicillin that went ashore with the troops on D-Day was made by Pfizer.
In the 1940s, penicillin became very inexpensive. As a result, Pfizer searched for new antibiotics with greater profit potential. Pfizer's discovery and commercialization of Terramycin (oxytetracycline) in 1950 changed the company from a manufacturer of fine chemicals to a research-based pharmaceutical company. To augment its research in fermentation technology, Pfizer developed a drug discovery program focusing on in vitro synthesis. Pfizer also established an animal health division in 1959 with an 700-acre (2.8 km2) farm and research facility in Terre Haute, Indiana.
By the 1950s, Pfizer had established offices in Belgium, Brazil, Canada, Cuba, Iran, Mexico, Panama, Puerto Rico, Turkey, and the United Kingdom. In 1960, the company moved its medical research laboratory operations out of New York City to a new facility in Groton, Connecticut. In 1980 Pfizer launched Feldene (piroxicam), a prescription anti-inflammatory medication that became Pfizer's first product to reach one billion United States dollars in total sales.
On June 26, 2006, Pfizer announced that it would sell its Consumer Healthcare unit (manufacturer of Listerine, Nicorette, Visine, Sudafed and Neosporin) to Johnson & Johnson for $16.6 billion.
Development of torcetrapib, a drug that increases production of HDL, or "good cholesterol", which reduces LDL thought to be correlated to heart disease, was cancelled in December 2006. During a Phase III clinical trial involving 15,000 patients, more deaths occurred in the group that took the medicine than expected, and a sixty percent increase in mortality was seen among patients taking the combination of torcetrapib and Lipitor versus Lipitor alone. Lipitor alone was not implicated in the results, but Pfizer lost nearly $1 billion developing the failed drug and the market value of the company plummeted in the aftermath.
A July 2010 article in BusinessWeek reported that Pfizer was seeing more success in its battle against makers of counterfeit prescription drugs by pursuing civil lawsuits rather than criminal prosecution. Pfizer has hired customs and narcotics experts from all over the globe to track down fakes and assemble evidence that can be used to pursue civil suits for trademark infringement. Since 2007, Pfizer has spent $3.3 million on investigations and legal fees and recovered about $5.1 million, with another $5 million tied up in ongoing cases.
Pfizer acquired Warner–Lambert in 2000 for $111.8 bn. Warner–Lambert was founded as a Philadelphia drug store in 1856 by William R. Warner. Inventing a tablet-coating process gained Warner a place in the Smithsonian Institution. Parke–Davis was founded in Detroit in 1866 by Hervey Parke and George Davis. Warner–Lambert took over Parke–Davis in 1976 and acquired Wilkinson Sword in 1993 and Agouron in 1999.
In 2002, Pfizer merged with Pharmacia. The merger was again driven in part by the desire to acquire full rights to a product, this time Celebrex (celecoxib), the COX-2 selective inhibitor previously jointly marketed by Searle (acquired by Pharmacia) and Pfizer. In the ensuing years, Pfizer commenced with a massive restructuring resulting in numerous site closures and loss of jobs including: Terre Haute, IN; Holland, MI; Groton, CT; Brooklyn, NY; Sandwich, UK and Puerto Rico.
Searle was founded in Omaha, Nebraska, in April 1888. The founder was Gideon Daniel Searle. In 1908, the company was incorporated in Chicago. In 1941, the company established headquarters in Skokie, Illinois. It was acquired by the Monsanto Company, headquartered in St. Louis, in 1985.
The Upjohn Company was a pharmaceutical manufacturing firm founded in 1886 in Kalamazoo, Michigan by Dr. William E. Upjohn, an 1875 graduate of the University of Michigan medical school. The company was originally formed to make friable pills, which were specifically designed to be easily digested. In 1995, Upjohn merged with Pharmacia, to form Pharmacia & Upjohn. Pharmacia was created in April 2000 through the merger of Pharmacia & Upjohn with the Monsanto Company and its G.D. Searle unit. The merged company was based in Peapack, New Jersey. The agricultural division was spun off from Pharmacia, as Monsanto, in preparation for the close of the acquisition by Pfizer.
SUGEN was a company focused on protein kinase inhibitors, founded in 1991 in Redwood City, California and acquired by Pharmacia in 1999. The company pioneered the use of ATP-mimetic small molecules to block signal transduction. After the Pfizer merger, the SUGEN site was shut down in 2003, with the loss of over 300 jobs, and the transfer of several programs to Pfizer. These included sunitinib (Sutent), which was approved for human use by the FDA in January 2006, passed $1 bn in annual revenues for Pfizer in 2010. A related compound SU11654 (Toceranib) was also approved for canine tumors, and the ALK inhibitor Crizotinib also grew out of a SUGEN program
In 2008, Pfizer announced 275 job cuts at the Kalamazoo manufacturing facility. Kalamazoo was previously the world headquarters for the Upjohn Company.
On January 26, 2009, after more than a year of talks between the two companies, Pfizer agreed to buy pharmaceuticals rival Wyeth for a combined US$68 billion in cash, shares and loans, including some US$22.5 billion lent by five major Wall Street banks. The deal cemented Pfizer's position as the largest pharmaceutical company in the world, with the merged company generating over US$20 billion in cash each year, and was the largest corporate merger since AT&T and BellSouth's US$70 billion deal in March 2006. The combined company was expected to save US$4 billion annually through streamlining; however, as part of the deal, both companies must repatriate billions of dollars in revenue from foreign sources to the United States, which will result in higher tax costs. The acquisition was completed on October 15, 2009, making Wyeth a wholly owned subsidiary of Pfizer.
The merger was broadly criticized. Harvard Business School’s Gary Pisano told The Wall Street Journal that "the record of big mergers and acquisitions in Big Pharma has just not been good. There’s just been an enormous amount of shareholder wealth destroyed". Said analysts at the time, "The Warner–Lambert and Pharmacia mergers do not appear to have achieved gains for shareholders, so it is unclear who benefits from the Wyeth–Pfizer merger to many critics."
King Pharmaceuticals acquisition
2011 to present
In February 2011 it was announced that Pfizer was to close its UK research and development facility (formerly also a manufacturing plant) in Sandwich, Kent, which at that time employed 2,400 people. However, as at 2014 Pfizer retains a reduced presence at the site; it also has a UK research unit at Cambridge.
On September 4, 2012, the FDA approved a Pfizer pill for a rare type of leukemia. The medicine, called Bosulif, treats chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.
Plans to spin out Zoetis, the Agriculture Division of Pfizer and later Pfizer Animal Health, were announced in 2012. Pfizer filed for registration of a Class A stock with the U.S. Securities and Exchange Commission on August 13, 2012. Zoetis' IPO on February 1, 2013 sold 86.1 million shares for US$ 2.2 billion. Pfizer retained 414 million Class B shares giving it an 83% controlling stake in the firm. The offering's lead underwriters were JPMorgan Chase, Bank of America, Merrill Lynch and Morgan Stanley. Most of the money raised through the IPO was used to pay off existing Pfizer debt.
Attempted AstraZeneca acquisition
In April 2014, it was reported that Pfizer had reignited a $100 billion takeover bid for the UK-based AstraZeneca, sparking political controversy in the UK, as well as in the US. On May 19, 2014 a "final offer" of £55 a share was rejected by the AstraZeneca board which said the bid was too low and it imposed too many risks. If successful the takeover, which would have been the biggest in British history, would have made Pfizer the world's largest drug company. Hopes for a renewed bid later in the year were dashed when the firm signed a major cancer drug deal with Merck KGaA, selling its sharing rights to develop an experimental immunotherapy drug for a fee of $850 million.
Pfizer is organised into nine principal operating divisions: Primary Care, Specialty Care, Oncology, Emerging Markets, Established Products, Consumer Healthcare, Nutrition, Animal Health, and Capsugel.
Research and development
Pfizer's research and development activities are organised into two principal groups: the PharmaTherapeutics Research & Development Group, which focuses on the discovery of small molecules and related modalities; and the BioTherapeutics Research & Development Group, which focuses on large-molecule research, including vaccines. In 2007, Pfizer invested $8.1 billion in research and development, the largest R&D investment in the pharmaceutical industry.
Pfizer has R&D facilities in the following locations: Groton, Connecticut; La Jolla, California (around 1,000 staff, focused on cancer drugs); South San Francisco, California; Cambridge, Massachusetts; Kalamazoo, Michigan; St. Louis, Missouri; Sandwich, United Kingdom; and Cambridge, United Kingdom.
In 2007, Pfizer announced plans to close or sell on the Loughbeg API facility, located at Loughbeg, Ringaskiddy Co. Cork Ireland by mid to end of 2008. In 2007, Pfizer announced plans to completely close the Ann Arbor, Nagoya and Amboise Research facilities by the end of 2008, eliminating 2,160 jobs and idling the $300-million dollar Michigan facility, which had seen millions of dollars of expansion in recent years.
On June 18, 2007 Pfizer announced that it would move the Animal Health Research (VMRD) division based in Sandwich, England to Kalamazoo, Michigan. On February 1, 2011 Pfizer announced the closure of the Research and Development centre in Sandwich, with the loss of 2,400 jobs. Pfizer subsequently announced that it would maintain a significant presence at Sandwich, with around 650 staff continuing to be based at the site.
On September 1, 2011 Pfizer announced that it had agreed to a 10-year lease of more than 180,000 square feet of research space from MIT in a building to be constructed at 610 Main Street South, just north of the MIT campus in Cambridge, Massachusetts, US. The space will house Pfizer’s Cardiovascular, Metabolic and Endocrine Disease Research Unit and its Neuroscience Research Unit — and Pfizer anticipates moving into the space once it is completed in late 2013.
Board of directors
As of November 2014, the members of the board of directors of Pfizer are:
- Dennis Ausiello
- W. Don Cornwell
- Frances D. Fergusson
- Helen Hobbs
- Constance Horner
- Ian Read (chairman)
- James M. Kilts
- George Lorch
- Suzanne Nora Johnson
- Shantanu Narayen
- Stephen Sanger
- James C. Smith
- Marc Tessier-Lavigne
- Chief Executive Officer (CEO) and Chairman of the Board: Ian Read
- Chief Financial Officer (CFO) and Executive Vice President: Frank A. D'Amelio
- Strategy and Business Development and Executive Vice President: Laurie Olsen
- Chief Compliance & Risk Officer and Executive Vice President: Rady Johnson
- Chief Medical Officer and Executive Vice President: Freda Lewis Hall
- General Counsel and Executive Vice President: Doug Lankler
- Chief Communications Officer and Executive Vice President: Sally Susman
- President of Global R&D: Mikael Dolsten
- President – Pfizer Global Manufacturing: Anthony Maddaluna
- Executive Vice President – Worldwide Human Resources: Chuck Hill
- President and General Manager, Global Innovative Pharmaceuticals: Geno Germano
- President and General Manager, Global Established Pharmaceuticals: John Young
- President and General Manager, Vaccines, Oncology and Consumer: Albert Bourla
Key current and historical Pfizer products include:
- Lipitor (atorvastatin), a statin for the treatment of hypercholesterolemia. Lipitor was developed by Pfizer legacy company Warner-Lambert and first marketed in 1996. Although atorvastatin was the fifth drug in the class of statins to be developed, clinical trials showed that atorvastatin caused a more dramatic reduction in LDL-C than the other statin drugs. From 1996 to 2012 under the trade name Lipitor, atorvastatin became the world's best-selling drug of all time, with more than $125 billion in sales over approximately 14.5 years.
- Prevnar (13-valent conjugate pneumococcal vaccine) is a vaccine for the prevention of invasive pneumococcal infections. The introduction of the original, 7-valent version of the vaccine in 1999 led to a 75% reduction in the incidence of invasive pneumococcal infections among children under age 5 in the United States. An improved version of the vaccine, providing coverage of 13 bacterial variants, was introduced in early 2010. As of 2012 the rate of invasive infections among children under age 5 has been reduced by an additional 50%.
- Norvasc (amlodipine), an antihypertensive drug of the dihydropyridine class. Amlodipine is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.
- Diflucan (flucoconazole), the first orally available treatment for severe fungal infections. Fluconazole is recommended as a first-line treatment in invasive candidiasis and is widely used in the prophylaxis of severe fungal infections in premature infants. Fluconazole is on the World Health Organization's List of Essential Medicines.
- Zithromax (azithromycin), a macrolide antibiotic that is recommended by the Infectious Disease Society of America as a first line treatment for certain cases of community-acquired pneumonia.
- Flagyl (metronidazole) is a nitroimidazole antibiotic medication used particularly for anaerobic bacteria and protozoa. It is antibacterial against anaerobic organisms, an amoebicide, and an antiprotozoal. It is the drug of choice for first episodes of mild-to-moderate Clostridium difficile infection. It is on the World Health Organization's List of Essential Medicines.
- Zoloft (sertraline), is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It was introduced to the market by Pfizer in 1991. Sertraline is primarily prescribed for major depressive disorder in adult outpatients as well as obsessive–compulsive, panic, and social anxiety disorders in both adults and children. In 2011, it was the second-most prescribed antidepressant on the U.S. retail market, with 37 million prescriptions.
- Selzentry (maraviroc), an HIV entry inhibitor useful for the treatment of multi-drug resistant HIV infection.
- Zyvox (linezolid), an antibiotic for the treatment of severe, multi-drug resistant bacterial infections.
- Lyrica (pregabalin) for neuropathic pain. Sales of Lyrica were $4.6 billion in 2013; the US patent on Lyrica was challenged by generic manufacturers and was upheld in 2014, giving Pfizer exclusivity for Lyrica in the US until 2018.
Pfizer's other pharmaceutical products include:
- Accupril (quinapril) for hypertension treatment.
- Accuretic (quinapril)
- Advil (ibuprofen) for pain and fever.
- Alavert (loratadine)
- Aldactazide (spironolactone)
- Aldactone (spironolactone)
- Alesse (levonorgestrel/ethinylestradiol) an oral contraceptive.
- Alsuma (sumatriptan)
- Aricept (donepezil) for Alzheimer's disease.
- Aromasin (exemestane) for the prevention of breast cancer and the prevention of osteoporosis and menopause for women.
- Arthrotec (diclofenac/misoprostol) an anti-inflammatory.
- Ativan (lorazepam) for anxiety and panic disorders.
- Bextra (Valdecoxib) for arthritis.
- Caduet (amlodipine) and (atorvastatin) for cholesterol and hypertension.
- Camptosar (irinotecan) for cancer and Chemotherapeutic agents.
- Celebrex (celecoxib) for arthritis.
- Chantix/Champix (Varenicline) for Nicotinic agonists, and anti nicotine drugs.
- Cefobid a cephalosporin antibiotic.
- Cyklokapron (tranexamic acid) for menorrhea.
- Depo-Medrol (methylprednisolone) for asthma.
- Solu-Medrol (methylprednisolone) for asthma.
- Depo Provera for birth control.
- Detrol and Detrol LA (tolterodine) for overactive bladder (OAB).
- Ellence (epirubicin) for cancer and chemotherapy drug.
- Eraxis (anidulafungin) an antifungal drug.
- Eryc (erythromycin) an antibiotic.
- Exubera (inhalable insulin) for diabetes, and insulin therapies.
- Flagyl (metronidazole) for bacterial and protozoal infections.
- Genotropin (Growth hormone) for growth failure due to an inadequate secretion of endogenous growth hormone.
- Geodon (ziprasidone) for schizophrenia and bipolar disorder.
- Inspra (eplerenone) for diuretics.
- Lipitor, Sortis (atorvastatin) for cholesterol.
- Macugen (pegaptanib) for wet age-related macular degeneration
- Neurontin (gabapentin) for neuropathic pain.
- Preparation H for hemorrhoids
- Relpax (eletriptan) for including the sulfonamide group of migraine.
- Rescriptor (delavirdine) for HIV.
- Somavert (pegvisomant) for Acromegaly.
- Sutent (sunitinib) for cancer and a chemotherapy drug.
- Toviaz (fesoterodine) for overactive bladder (OAB).
- Tikosyn (dofetilide) for atrial fibrillation and flutter.
- Vfend (voriconazole) for antifungal drug.
- Viagra (sildenafil) for erectile dysfunction.
- Viracept (nelfinavir) for AIDS.
- Xalatan (latanoprost) for glaucoma
- Xalacom latanoprost and timolol Medication for glaucoma.
- Xanax and Xanax XR (alprazolam) for anxiety and panic disorders.
In addition to marketing branded pharmaceuticals, Pfizer is involved in the manufacture and sale of generics. In the US it does this through its Greenstone subsidiary which it acquired as part of the acquisition of Pharmacia. Pfizer also has a licensing deal in place with Aurobindo which grants the former access to a variety of oral solid generic products.
Consumer healthcare products
Pfizer's consumer healthcare products include:
Access to Wyeth internal documents has revealed marketing strategies used to promote Neurontin for off-label use. In 1993, the U.S. Food and Drug Administration (FDA) approved gabapentin (Neurontin, Pfizer) only for treatment of seizures. Warner–Lambert, which merged with Pfizer in 2000, used activities not usually associated with sales promotion, including continuing medical education and research, sponsored articles about the drug for the medical literature, and alleged suppression of unfavorable study results, to promote gabapentin. Within 5 years the drug was being widely used for the off-label treatment of pain and psychiatric conditions. Warner–Lambert admitted to charges that it violated FDA regulations by promoting the drug for pain, psychiatric conditions, migraine, and other unapproved uses, and paid $430 million to resolve criminal and civil health care liability charges. A recent Cochrane review concluded that gabapentin is ineffective in migraine prophylaxis. The American Academy of Neurology rates it as having unproven efficy, while the Canadian Headache Society and the European Federation of Neurological Societies rate its use as being supported by moderate and low-quality evidence, respectively.
In September 2009, Pfizer agreed to pay $2.3 billion to settle civil and criminal allegations that it had illegally marketed four drugs—Bextra, Geodon, Zyvox, and Lyrica—"for non-approved uses; it was Pfizer's fourth such settlement in a decade. The payment included $1.3 billion in criminal penalties for felony violations of the Food, Drug and Cosmetic Act, and $1 billion to settle allegations it had illegally promoted the drugs for uses that were not approved by the U.S. Food and Drug Administration (FDA) and caused false claims to be submitted to Federal and State programs. The criminal fine was the largest ever assessed in the United States up to that time. Pfizer has entered an extensive corporate integrity agreement (CIA) with the Office of Inspector General and will be required to make substantial structural reforms within the company, and maintain the Pfizer website (www.pfizer.com/pmc) to track the company's post marketing commitments. Pfizer must also put a searchable database of all payments to physicians the company has made on the Pfizer website by March 31, 2010.
Peter Rost was vice president in charge of the endocrinology division at Pharmacia before and during its acquisition by Pfizer. During that time he raised concerns internally about kickbacks and off-label marketing of Genotropin, Pharmacia's human growth hormone drug. Pfizer reported the Pharmacia marketing practices to the FDA and Department of Justice; Rost was unaware of this and filed an FCA lawsuit against Pfizer. Pfizer kept him on, but isolated him until the FCA suit was unsealed in 2005. The Justice Department declined to intervene, and Pfizer fired him, and he filed a wrongful termination suit against Pfizer. 
A "whistleblower suit" was filed in 2005 against Wyeth, which was acquired by Pfizer, alleging that the company illegally marketed their drug Rapamune. Wyeth is targeted in the suit for off-label marketing, targeting specific doctors and medical facilities to increased sales of Rapamune, trying to get current transplant patients to change from their current transplant drugs to Rapamune and for specifically targeting African-Americans. According to the whistleblowers, Wyeth also provided doctors and hospitals with kickbacks to prescribe the drug in the form of grants, donations and other money. In 2013, the company pleaded guilty to criminal mis-branding violations under the Food, Drug and cosmetic act. By August 2014 it had paid $491 million in civil and criminal penalties.
According to Harper's Magazine publisher John MacArthur, Pfizer withdrew "between $400,000 and a million dollars" worth of ads from their magazine following an unflattering article on depression medication.
The Supreme Court's 2005 decision in Kelo v. City of New London handed local governments the right to seize private property for economic development, i.e., offices and a hotel, to enhance Pfizer Inc.'s nearby corporate facility. However, following the completion of the aforementioned Wyeth merger, Pfizer announced it would close its research and development headquarters in New London, Connecticut, moving employees to nearby Groton. The property is now owned and operated by Electric Boat.
Pfizer acquired Quigley in 1968, and the division sold asbestos-containing insulation products until the early 1970s. Asbestos victims and Pfizer have been negotiating a settlement deal which calls for Pfizer to pay $430 million to 80 percent of existing plaintiffs. It will also place an additional $535 million into an asbestos settlement trust that will compensate future plaintiffs as well as the remaining 20 percent of current plaintiffs with claims against Pfizer and Quigley. The compensation deal is worth $965 million all up. Of that $535 million, $405 million is in a 40-year note from Pfizer, while $100 million will come from insurance policies.
Bjork–Shiley heart valve
Pfizer purchased Shiley in 1979 at the onset of its Convexo-Concave valve ordeal, involving the Bjork–Shiley heart valve. Approximately 500 people died when defective valves failed and, in 1994, the United States ruled against Pfizer for ~$200 million.
Abdullahi v. Pfizer, Inc.
In 1996, an outbreak of measles, cholera, and bacterial meningitis occurred in Nigeria. Pfizer representatives traveled to Kano, Nigeria to administer an experimental antibiotic, trovafloxacin, to approximately 200 children. Local Kano officials report that more than 50 children died in the experiment, while many others developed mental and physical deformities. The nature and frequency of both fatalities and other adverse outcomes were similar to those historically found among pediatric patients treated for meningitis in sub-Saharan Africa. In 2001, families of the children, as well as the governments of Kano and Nigeria, filed lawsuits regarding the treatment. According to the news program Democracy Now!, "[r]esearchers did not obtain signed consent forms, and medical personnel said Pfizer did not tell parents their children were getting the experimental drug." The lawsuits also accuse Pfizer of using the outbreak to perform unapproved human testing, as well as allegedly under-dosing a control group being treated with traditional antibiotics in order to skew the results of the trial in favor of Trovan. While the specific facts of the case remain in dispute, both Nigerian medical personnel and at least one Pfizer physician have stated that the trial was conducted without regulatory approval.
In 2007, Pfizer published a Statement of Defense letter. The letter states that the drug's oral form was safer and easier to administer, that Trovan had been used safely in over 5000 Americans prior to the Nigerian trial, that mortality in the patients treated by Pfizer was lower than that observed historically in African meningitis epidemics, and that no unusual side effects, unrelated to meningitis, were observed after 4 weeks.
In June 2010, the US Supreme Court rejected Pfizer's appeal against a ruling allowing lawsuits by the Nigerian families to proceed.
In December 2010, WikiLeaks released US diplomatic cables, which indicate that Pfizer had hired investigators to find evidence of corruption against Nigerian attorney general Aondoakaa to persuade him to drop legal action. Washington Post reporter Joe Stephens, who helped break the story in 2000, called these actions "dangerously close to blackmail." In response, the company has released a press statement describing the allegations as "preposterous" and stating that they acted in good faith. Aondoakka, who had allegedly demanded bribes from Pfizer in return for a settlement of the case, was declared unfit for office and had his U.S. visa revoked in association with corruption charges in 2010.
A scientist claims she was infected by a genetically modified virus while working for Pfizer. In her federal lawsuit she says she has been intermittently paralyzed by the Pfizer-designed virus. "McClain, of Deep River, suspects she was inadvertently exposed, through work by a former Pfizer colleague in 2002 or 2003, to an engineered form of the lentivirus, a virus similar to the one that can lead to acquired immune deficiency syndrome, or AIDS." The court found that McClain failed to demonstrate that her illness was caused by exposure to the lentivirus, but also that Pfizer violated whistleblower laws.
Blue Cross Blue Shield
Health insurance company Blue Cross Blue Shield (BCBS) filed a lawsuit against Pfizer for reportedly illegally marketing their drugs Bextra, Geodon and Lyrica. BCBS is reporting that Pfizer used "kickbacks" and wrongly persuaded doctors to prescribe the drugs. FiercePharma reported that "According to the suit, the drugmaker not only handed out those "misleading" materials on off-label uses, but sent doctors on Caribbean junkets and paid them $2,000 honoraria in return for their listening to lectures about Bextra. More than 5,000 healthcare professionals were entertained at meetings in Bahamas, Virgin Islands and across the U.S., the suit alleges." The case was settled in 2014 for $325M.
Brigham Young University
Controversy arose over the drug "Celebrex." Brigham Young University (BYU) said that a professor of chemistry, Dr. Daniel Simmons, discovered an enzyme in the 1990s which would later lead towards the development of Celebrex. BYU was originally seeking 15% royalty on sales which would equate to $9.7 billion. The court filings show that a research agreement was made with Monsanto, whose pharmaceutical business was later acquired by Pfizer, to develop a better aspirin. The enzyme that Dr. Simmons claims to have discovered would induce pain and inflammation while causing gastrointestinal problems, which Celebrex is used to reduce those issues. A battle ensued, lasting over six years, because BYU claimed that Pfizer did not give him credit or compensation while Pfizer claims it had met all obligations regarding the Monsanto agreement. This culminated in a $450 million amicable settlement without going to trial. Pfizer said it would take a $450 million charge against first quarter earnings to settle.
Between 2002 and 2008, Pfizer reduced its greenhouse emissions by 20%, and committed to reducing emissions by an additional 20% by 2012. In 2012 the company was named to the Carbon Disclosure Project's Carbon Leadership Index in recognition of its efforts to reduced greenhouse gas emissions.
Pfizer has inherited Wyeth's liabilities in the American Cyanamid site in Bridgewater, New Jersey. This site is highly toxic and an EPA declared Superfund site. Pfizer has since attempted to remediate this land in order to clean and develop it for future profits and potential public uses. The Sierra Club and the Edison Wetlands Association have come out in opposition to the cleanup plan, arguing that pollutants the area is subject to flooding, which could cause pollutants to leach. The EPA considers the plan the most reasonable from considerations of safety and cost-effectiveness, arguing that an alternative plan involving trucking contaminated soil off site could expose cleanup workers. The EPA's position is backed by the environmental watchdog group CRISIS.
In June 2002, a chemical explosion at the Groton plant injured seven people and caused the evacuation of over 100 homes in the surrounding area.
Pfizer is a leading member of the U.S. Global Leadership Coalition, a Washington D.C.-based coalition of over 400 major companies and NGOs that advocates for a larger International Affairs Budget, which funds American diplomatic, humanitarian, and development efforts abroad.
Employment and diversity
Pfizer received a 100% rating on the Corporate Equality Index released by the Human Rights Campaign starting in 2004, the third year of the report. In 2007, Pfizer's Canadian division was named one of Canada's Top 100 Employers, as published in Maclean's magazine, the only research-based pharmaceutical company to receive this honor.
Involvement in Developing World Health Issues
The company has also pledged to provide up to 480 million doses of its anti-pneumococcal vacccine at deeply discounted rates to children and infants in developing countries in collaboration with the GAVI Alliance.
In 2012 Pfizer and the Gates Foundation announced a joint effort to provide 3 million women in the developing world with affordable access to Pfizer's long lasting injectable contraceptive, medroxyprogesterone acetate.
- "PFIZER INC 2013 Annual Report Form (10-K)" (XBRL). United States Securities and Exchange Commission. February 28, 2014.
- Ian C. Read (February 28, 2014). "CEO Letter" (PDF). 2013 Annual Review. Pfizer.
- "Frequently Asked Questions". Pfizer. Corporate Mailing Address. Retrieved October 24, 2014.
- "Pfizer moves higher amid persistent breakup talk". Bloomberg Businessweek. 27 March 2012. Retrieved 8 July 2012.
- Andrew Ross Sorkin and Duff Wilson (January 26, 2009). "Pfizer Agrees to Pay $68 billion for Rival Drug Maker Wyeth". The New York Times.
- "Wyeth Transaction". Pfizer. Retrieved October 25, 2009.
- Dow Jones Industrial Average Historical Components from moneycontrol.com
- "Pfizer pays $2.3 billion to settle marketing case", The New York Times, September 2, 2009.
- Harris, Gardiner (September 3, 2009). "Pfizer Pays $2.3 billion to Settle Marketing Case". The New York Times.
- Johnson, Carrie (September 3, 2009). "In Settlement, A Warning To Drugmakers: Pfizer to Pay Record Penalty In Improper-Marketing Case". The Washington Post.
- Kenneth T. Jackson. [yalepress.yale.edu/yupbooks/book.asp?isbn= 9780300055368 The Encyclopedia of New York City]. The New York Historical Society; Yale University Press; September 1995. P. 895. ISBN 978-0-300-05536-8
- "Charles Pfizer". Pfizer. Retrieved 9 December 2014.
- "A Plan For Big Pharma Involvement In Superbug R&D". 7/16/2014. Retrieved 9 August 2014. Check date values in:
- "Johnson & Johnson to Buy Pfizer Unit". MoneyNews.com. June 26, 2006. Retrieved July 19, 2007.[dead link]
- "Johnson & Johnson Completes Acquisition Of Pfizer Consumer Healthcare" (Press release). Johnson & Johnson. December 20, 2006.
- Saul, Stephanie (June 27, 2006). "Johnson & Johnson Buys Pfizer Unit for $16.6 billion". The New York Times.
- Pfizer Shares Plummet on Loss of a Promising Heart Drug By ALEX BERENSON and ANDREW POLLACK. December 5, 2006. The New York Times
- Berenson, Alex (December 3, 2006). "Pfizer Ends Studies on Drug for Heart Disease". The New York Times. Retrieved December 3, 2006.
- Theresa Agovino (Associated Press) (December 3, 2006). "Pfizer ends cholesterol drug development". Yahoo! News. Retrieved December 3, 2006.[dead link] Each study arm (torcetrapib + Lipitor vs. Lipitor alone) had 7500 patients enrolled; 51 deaths were observed in the Lipitor alone arm, while 82 deaths occurred in the torcetrapib + Lipitor arm.
- Bennett, Simeon (July 8, 2010). "Pfizer: Civil Suits for Drug Counterfeiters". BusinessWeek. Retrieved July 11, 2011.
- "Pfizer to sell Viagra online, in first for Big Pharma: AP". CBS News. Retrieved 6 May 2013.
- Pfizer, 2000: Pfizer joins forces with Warner–Lambert, accessed April 7, 2010
- "Pharmacia to Spin Off Monsanto Stake, Less Than 2 Years After Firms' Merger Wall Street Journal 28nov01".
- "Pfizer 2010 annual financial review, p 25." (PDF). Retrieved July 11, 2011.
- "Pfizer Drug Targets Gene Flaw to Shrink Lung Tumors (Update1)". Businessweek. Retrieved July 11, 2011.
- "Pfizer plant in Michigan to cut 275 – FiercePharma".
- Pfizer Agrees to Pay $68 billion for Rival Drug Maker Wyeth By ANDREW ROSS SORKIN and DUFF WILSON. January 26, 2009. The New York Times
- The Pfizer–Wyeth Deal Worst-Case Scenario By Jim Edwards | January 23, 2009 – BNET
- Matthew Karnitschnig, & Jonathan D. Rockoff. (2009, January 23). Pfizer in Talks to Buy Wyeth. Wall Street Journal (Eastern Edition), p. A.1. Retrieved March 7, 2010, from Wall Street Journal. (Document ID: 1631280041).
- "Pfizer to buy King Pharma for $3.6 billion in cash". Reuters. October 12, 2010. Retrieved October 12, 2010.
- "Pfizer to close UK research site". BBC News. February 1, 2011.
- Pfizer R&D Locations: Sandwich, UK
- Pfizer R&D Locations: Cambridge, UK
- "FDA approves Pfizer leukemia drug". Reuters. Retrieved 4 September 2012.
- "Zoetis™ Files IPO Registration Statement". Bloomberg L.P. New York. August 13, 2012. Retrieved 1 February 2013.
- J. DE LA MERCED, MICHAEL (February 1, 2013). "Shares of Zoetis Surge on Debut". New York Times (New York). Retrieved 1 February 2013.
- DIETERICH, CHRIS (January 31, 2013). "Zoetis Raises $2.2 Billion in IPO - WSJ.com". The Wall Street Journal (New York). Retrieved 1 February 2013.
- "Shares of animal health company Zoetis soar in IPO". CBS News (New York). February 1, 2013. Retrieved 1 February 2013.
- Ben Hirschler (28 April 2014). "Pfizer chases AstraZeneca for potential $100 billion deal". Reuters.
- Brozak, Steve. "No Longer King Of The North, Pfizer Looks To Recapture Crown". Forbes. Retrieved 30 April 2014.
- Cameron and Miliband clash over Pfizer deal, BBC News, May 7, 2014.
- US politicians raise questions over Pfizer bid, BBC News, May 9, 2014.
- "AstraZeneca rejects Pfizer 'final' takeover offer, triggers major drop in shares". London Mercury. Retrieved May 20, 2014.
- Pfizer dampens Astra bid hopes with German Merck cancer deal. Reuters, 17 November 2014
- "Pfizer Leadership and Structure". Pfizer. Retrieved 6 January 2013.
- "Annual Review 2007 | Pfizer: the world's largest research-based pharmaceutical company". Pfizer. October 9, 2009. Retrieved July 11, 2011.
- Pollack, Andrew (September 2, 2009). "For Profit, Industry Seeks Cancer Drugs". The New York Times. Retrieved September 3, 2009.
- Pfizer's cuts blindside Ann Arbor workers, Kalamazoo Gazette, Sunday, January 23, 2007.
- Pfizer Reorganization Could Bring Jobs To Kalamazoo, WWMT.com, June 18, 2007
- "Drug giant Pfizer to pull out of Kent". Kentonline.co.uk. February 1, 2011. Retrieved July 11, 2011.
- "Pfizer site in Sandwich set to retain 650 jobs". BBC News. 4 November 2011. Retrieved 9 July 2012.
- "Pfizer Expands its Research Footprint in Cambridge". MITnews. September 1, 2011.
- "Meet the Pfizer Board of Directors". Pfizer. Retrieved 6 November 2014.
- "Pfizer's Jeffrey Kindler resigns as chief executive". BBC News. December 6, 2010. Retrieved December 6, 2010.
- "CDC - ABCs: Surveillance Reports main page - Active Bacterial Core surveillance".
- "Lipitor becomes world's top-selling drug". Crain's New York Business. 2011-12-28.
- "WHO Model List of EssentialMedicines". World Health Organization. October 2013. Retrieved 22 April 2014.
- Charlier C, Hart E, Lefort A, et al. (March 2006). "Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?". J. Antimicrob. Chemother. 57 (3): 384–410. doi:10.1093/jac/dki473. PMID 16449304.
- Blyth CC, Barzi F, Hale K, Isaacs D (September 2012). "Chemoprophylaxis of neonatal fungal infections in very low birthweight infants: efficacy and safety of fluconazole and nystatin". J Paediatr Child Health 48 (9): 846–51. doi:10.1111/j.1440-1754.2012.02543.x. PMID 22970680.
- Mandell LA, Wunderink RG, Anzueto A, et al. (March 2007). "Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults". Clin. Infect. Dis. 44 Suppl 2: S27–72. doi:10.1086/511159. PMID 17278083.
- [. Retrieved 3 April 2014. "Metronidazole monograph"]. drugs.com
- Cohen, S. H.; Gerding, D. N.; Johnson, S.; Kelly, C. P.; Loo, V. G.; McDonald, L. C.; Pepin, J.; Wilcox, M. H.; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America (2010). "Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)". Infection Control and Hospital Epidemiology 31 (5): 431–455. doi:10.1086/651706. PMID 20307191.
- John M. Grohol (2012). "Top 25 Psychiatric Medication Prescriptions for 2011". Psych Central. Retrieved 9 January 2013.
- Pichenot M, Deuffic-Burban S, Cuzin L, Yazdanpanah Y (March 2012). "Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials". HIV Med. 13 (3): 148–55. doi:10.1111/j.1468-1293.2011.00953.x. PMID 22107456.
- Pfizer (2010-07-16). "Zyvox (linezolid) Label Information" (PDF). Retrieved 2011-04-02.
- Susan Decker for Bloomberg News. Feb 6, 2014. Pfizer Wins Ruling to Block Generic Lyrica Until 2018
- "Pfizer Prescription Products". Pfizer Inc. Retrieved March 9, 2010.
- Hollis, Liz "Greenstone – Top 10 Generic Drug Companies 2010" Fierce Pharma, August 10, 2010
- "Greenstone press releases" Greenstone corporate website, Retrieved November 3, 2010
- Steinman MA, Bero LA, Chren MM, Landefeld CS (August 2006). "Narrative review: the promotion of gabapentin: an analysis of internal industry documents". Ann. Intern. Med. 145 (4): 284–93. doi:10.7326/0003-4819-145-4-200608150-00008. PMID 16908919. Retrieved December 2, 2009.
- The settlement was the first off-label promotion case successfully brought under the False Claims Act. Henney JE (August 2006). "Safeguarding patient welfare: who's in charge?". Ann. Intern. Med. 145 (4): 305–7. doi:10.7326/0003-4819-145-4-200608150-00013. PMID 16908923. Retrieved December 2, 2009.
- "Warner–Lambert to pay $430 million to resolve criminal & civil health care liability relating to off-label promotion" (Press release). US Department of Justice. May 13, 2004. Retrieved December 2, 2009.
- Mulleners WM, McCrory DC, Linde M (August 2014). "Antiepileptics in migraine prophylaxis: An updated Cochrane review". Cephalalgia. doi:10.1177/0333102414534325. PMID 25115844.
- Loder E, Burch R, Rizzoli P (June 2012). "The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines". Headache 52 (6): 930–45. doi:10.1111/j.1526-4610.2012.02185.x. PMID 22671714.
- "Pfizer agrees record fraud fine". BBC. September 2, 2009. Retrieved May 22, 2010.
- The United States Department of Justice – United States Attorney's Office – District of Massachusetts[dead link]
- Jim Edwards for BrandWeek. March 20, 2006. Bad Medicine. BrandWeek. Original link broken, Created link from internet archive on August 9, 2014. Archive date March 28, 2006.
- "Wyeth Marketing Targeted Blacks Illegally: Lawsuit // Pharmalot". Pharmalot.com. May 24, 2010. Retrieved July 11, 2011.
- Tracy Staton (June 14, 2010). "Congress joins probe into Wyeth's Rapamune marketing". FiercePharma. Retrieved July 11, 2011.
- "Pfizer settles more off-label marketing cases tied to Rapamune - FiercePharma".
- Petrovich, Dushko (March 15, 2013). "The Art of Making Magazines edited by Victor S. Navasky and Evan Cornog". Bookforum. Retrieved 2013-03-18.
-  Kelo v. New London: Opinion of the Court
-  Quigley Company reorganization
- Blackstone, E.H., 2005. Could It Happen Again?: The Bjork–Shiley Convexo-Concave Heart Valve Story" Circulation 111(21), 2717–2719.
- Bloomfield, P. et al., 1991. Twelve-year comparison of a Bjork–Shiley mechanical heart valve with porcine bioprostheses" N Engl J Med 324(9), 573–579.
- Murray, Senan (June 20, 2007). "Africa | Anger at deadly Nigerian drug trials". BBC News. Retrieved July 11, 2011.
- Ramakrishnan M, Ulland AJ, Steinhardt LC, Moïsi JC, Were F, Levine OS (2009). "Sequelae due to bacterial meningitis among African children: a systematic literature review". BMC Med 7: 47. doi:10.1186/1741-7015-7-47. PMC 2759956. PMID 19751516.
- "Nigerians sue Pfizer over test deaths". BBC News. August 30, 2001. Retrieved May 22, 2010.
- WikiLeaks Cables: Pfizer Targeted Nigerian Attorney General to Undermine Suit over Fatal Drug Tests, Democracy Now!
- Panel Faults Pfizer in '96 Clinical Trial In Nigeria. The Washington Post. May 7, 2006
- "Pfizer Bribed Nigerian Officials in Fatal Drug Trial, Ex-Employee Claims - CBS News".
- "Trovan, Kano State Civil Case – Statement Of Defense" (PDF). Retrieved July 11, 2011.
- "Pfizer-Nigeria appeal dismissed". BBC News. June 29, 2010.
- Boseley, Sarah (December 9, 2010). "WikiLeaks cables: Pfizer 'used dirty tricks to avoid clinical trial payout'". The Guardian (London).
- "Press Statement Regarding Article in The Guardian" (PDF). Pfizer. December 9, 2010. Retrieved December 13, 2010.
- "In Defense of Blackmail: Why Shouldn't Pfizer Dig Dirt on Crooked Pols? - CBS News".
- "Michael Aondoakaa "Unfit" To Remain SAN, Says CDHR In High-Powered Petition | Sahara Reporters".
- "USAfrica: The Authoritative Link for Africans and Americans".
- "Ex-Pfizer Worker Cites Genetically Engineered Virus In Lawsuit Over Firing". Courant.com. March 14, 2010. Retrieved July 11, 2011.
- "McClain v. PFIZER, INC., 692 F. Supp. 2d 229". Retrieved September 13, 2012.
- "A Pfizer Whistle-Blower Is Awarded $1.4 Million". The New York Times. April 2, 2010. Retrieved September 13, 2012.
- "Blue Cross Names and Shames Pfizer Execs Linked to Massages-for-Prescriptions Push | BNET". Industry.bnet.com. June 10, 2010. Retrieved July 11, 2011.
- Bounds, Jeff (June 10, 2010). "Blue Cross Blue Shield of Texas sues Pfizer".
- Tracy Staton (June 11, 2010). "BCBS names Pfizer managers in kickback suit". FiercePharma. Retrieved July 11, 2011.
- "Blue Cross Blue Shield of Texas sues Pfizer over drug marketing | News for Dallas, Texas | Dallas Morning News | Dallas Business News". Dallasnews.com. June 11, 2010. Retrieved July 11, 2011.
- "Pfizer Agrees to $325 Million Neurontin Marketing Accord - Bloomberg".
- "Pfizer Commended For Leadership In Addressing Climate Change For Third Consecutive Year - FierceBiotech".
- "Pfizer Recognized by Carbon Disclosure Project for Carbon Performance | Pfizer: One of the world’s premiere biopharmaceutical companies".
- "Activists say EPA $204M fix for polluted American Cyanamid property will not permanently resolve problem | NJ.com".
- The tempest. The Washington Post. May 28, 2006
- "U.S. Global Leadership Coalition, Global Trust members". Usglc.org. Retrieved July 11, 2011.
- "Reasons for Selection, 2007 Canada's Top 100 Employers".
- "AIDS Fungus Drug Offered to Poor Nations". June 7, 2001. Retrieved 10 August 2014.
- Sithole, Emelia (February 21, 2001). "S.Africa okays Pfizer AIDS drug distribution". Reuters NewMedia. Retrieved May 15, 2006.
- "Pfizer - Diflucan Commitments". Retrieved 2014-08-09.
- "Pfizer - GAVI commitments". Retrieved 2014-08-09.
- "Pfizer Gates Foundation Press Release". Retrieved 2014-08-09.